JP2013522363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522363A5 JP2013522363A5 JP2013501347A JP2013501347A JP2013522363A5 JP 2013522363 A5 JP2013522363 A5 JP 2013522363A5 JP 2013501347 A JP2013501347 A JP 2013501347A JP 2013501347 A JP2013501347 A JP 2013501347A JP 2013522363 A5 JP2013522363 A5 JP 2013522363A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridyl
- compound according
- halo
- thienyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 46
- 125000001475 halogen functional group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- -1 4-furyl Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000027520 Somatoform disease Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000027753 pain disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- KNOYHJOPRUTPSQ-QHCPKHFHSA-N (4s)-5-amino-5-oxo-4-[3-[4-(4-phenylphenyl)phenyl]propanoylamino]pentanoic acid Chemical compound C1=CC(CCC(=O)N[C@@H](CCC(O)=O)C(=O)N)=CC=C1C1=CC=C(C=2C=CC=CC=2)C=C1 KNOYHJOPRUTPSQ-QHCPKHFHSA-N 0.000 claims description 2
- 208000017194 Affective disease Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 2
- 230000007131 anti Alzheimer effect Effects 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000000648 anti-parkinson Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 239000000939 antiparkinson agent Substances 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 230000009245 menopause Effects 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000003402 opiate agonist Substances 0.000 claims description 2
- 239000003401 opiate antagonist Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 2
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 2
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 230000001457 vasomotor Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 229940125794 sodium channel blocker Drugs 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 0 *c(c(*)c1*)c(*)c(*)c1OCC1/C=C/C/C=C/CC1C1CCNCC1 Chemical compound *c(c(*)c1*)c(*)c(*)c1OCC1/C=C/C/C=C/CC1C1CCNCC1 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31609010P | 2010-03-22 | 2010-03-22 | |
| US61/316,090 | 2010-03-22 | ||
| PCT/US2011/029138 WO2011119461A1 (en) | 2010-03-22 | 2011-03-21 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522363A JP2013522363A (ja) | 2013-06-13 |
| JP2013522363A5 true JP2013522363A5 (enExample) | 2014-02-13 |
| JP5769348B2 JP5769348B2 (ja) | 2015-08-26 |
Family
ID=44211953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501347A Expired - Fee Related JP5769348B2 (ja) | 2010-03-22 | 2011-03-21 | １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8530663B2 (enExample) |
| EP (1) | EP2550252B1 (enExample) |
| JP (1) | JP5769348B2 (enExample) |
| ES (1) | ES2543064T3 (enExample) |
| WO (1) | WO2011119461A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011005089A (es) | 2008-11-14 | 2011-07-29 | Theravance Inc | Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina. |
| WO2011085291A1 (en) * | 2010-01-11 | 2011-07-14 | Theravance, Inc. | 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors |
| US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
| AU2020215042A1 (en) * | 2019-01-31 | 2021-08-19 | Ideaya Biosciences, Inc. | Heteroarylmethylene derivatives as DNA Polymerase Theta inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| DE2549999A1 (de) * | 1975-11-07 | 1977-05-12 | Boehringer Mannheim Gmbh | Piperidin-derivate und verfahren zu ihrer herstellung |
| IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
| US4179563A (en) * | 1978-05-19 | 1979-12-18 | Warner-Lambert Company | 3-Aryloxy-substituted-aminopyridines and methods for their production |
| US4198417A (en) * | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
| EP0190496A3 (en) | 1984-12-13 | 1987-05-27 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
| DE3541097A1 (de) * | 1985-11-21 | 1987-05-27 | Miles Lab | Verwendung von thiophenen als ph indikatoren insbesondere in einem nicht-enzymatischen glukosetest |
| US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| DE3835291A1 (de) * | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
| GB9324018D0 (en) * | 1993-11-23 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
| US6518284B2 (en) * | 1998-11-18 | 2003-02-11 | Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. | 4-substituted piperidines |
| US6630504B2 (en) * | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
| US7294637B2 (en) * | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| EP1534291B1 (en) * | 2002-08-23 | 2008-11-12 | Eli Lilly And Company | 2-(phenylthiomethyl)- morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
| EP1635828B1 (en) * | 2003-04-04 | 2008-04-23 | H. Lundbeck A/S | 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
| AU2004247487B2 (en) * | 2003-06-17 | 2010-05-20 | Pfizer Inc. | N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
| BRPI0506844A (pt) * | 2004-01-13 | 2007-06-12 | Pfizer | derivados de piperazina que apresentam atividade como inibidores da reabsorção de serotonina noradrenalina |
| EP1725518A1 (en) * | 2004-03-05 | 2006-11-29 | Eli Lilly And Company | Pharmaceutical compounds |
| EA200601798A1 (ru) * | 2004-04-30 | 2007-04-27 | Уорнер-Ламберт Компани Ллс | Замещенные соединения морфолина для лечения расстройств центральной нервной системы |
| US7482350B2 (en) * | 2004-05-08 | 2009-01-27 | Neurogen Corporation | 4,5-disubstituted-2-aryl pyrimidines |
| CA2661187A1 (en) | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Piperidine derivatives |
| US8026257B2 (en) * | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| TW200918521A (en) * | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
| WO2009081259A1 (en) * | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
| AU2009271414A1 (en) * | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl GPR119 agonists and uses thereof |
| MX2011005089A (es) * | 2008-11-14 | 2011-07-29 | Theravance Inc | Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina. |
| WO2010129055A1 (en) * | 2009-05-08 | 2010-11-11 | Tetraphase Pharmaceuticals, Inc. | 8-aza tetracycline compounds |
-
2011
- 2011-03-21 ES ES11714878.3T patent/ES2543064T3/es active Active
- 2011-03-21 WO PCT/US2011/029138 patent/WO2011119461A1/en not_active Ceased
- 2011-03-21 JP JP2013501347A patent/JP5769348B2/ja not_active Expired - Fee Related
- 2011-03-21 US US13/052,273 patent/US8530663B2/en not_active Expired - Fee Related
- 2011-03-21 EP EP20110714878 patent/EP2550252B1/en not_active Not-in-force
-
2013
- 2013-08-09 US US13/963,255 patent/US20130324550A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012521994A5 (enExample) | ||
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| JP2014508811A5 (enExample) | ||
| WO2008035358A3 (en) | Process for preparing dapoxetine | |
| CA2713025A1 (en) | Kappa selective opioid receptor antagonist | |
| JP2011529069A5 (enExample) | ||
| BR112014005389A8 (pt) | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal | |
| CY1110075T1 (el) | Παρασκευη(2r,3r)-3-(3-μεθοξυφαινυλ)-ν,ν,2-τριμεθυλοπενταναμινης | |
| JP2014500861A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| GEP20125566B (en) | Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | |
| IN2014KN00948A (enExample) | ||
| JP2012521428A5 (enExample) | ||
| EA201101308A1 (ru) | Применение ралфинамида для лечения биполярного расстройства | |
| RU2012142180A (ru) | Ингибиторы катехол-о-метилтрансферазы и их применение для лечения психотических расстройств | |
| NO20073208L (no) | 4-fenylsubstituerte tetrahydrotsokindiner og anvendelse derav til a blokkere gjenopptak av norepinefrin, dopamin og serotonin | |
| JP2013522363A5 (enExample) | ||
| EA201000280A1 (ru) | Фармацевтические композиции, содержащие лиганды дофаминовых рецепторов, и способы лечения с помощью лигандов дофаминовых рецепторов | |
| WO2010011811A4 (en) | 3-(phenoxyphenylmethyl)pyrrolidine compounds | |
| MY151211A (en) | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | |
| MX2012000685A (es) | Compuesto de 3-fenoximetilpirrolidina. | |
| JP2011527678A5 (enExample) | ||
| JP2015502973A5 (enExample) | ||
| JP2014518552A5 (enExample) | ||
| MX2007006082A (es) | Tetrahidroisoquinolinas aril- y heteroaril-sustituidas, y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina. |